Lenalidomide instructions

Lenalidomide is mainly used to treat inherited myelodysplasia and dependent anemia syndrome caused by certain cells. In addition, this drug has been widely used all over the world so far, and its efficacy and effects are extremely wide-ranging, so it is necessary to understand the relevant uses and precautions of this drug.

Boiling point: 614°C at 760 mmHg Flash point: 325.1°C

Vapor pressure: 5.2E-15mmHg at 25°C

Introduction Lenalidomide (Revlimid) FDA approved Revlimid for the treatment of myelodysplastic syndrome.

The U.S. Food and Drug Administration (FDA) has approved lenalidomide (revlimid) from CellGene Corporation. Revlimid is an oral preparation. Evlimid (lenalidomide) is a drug developed by Celgene for the treatment of fatal blood diseases and cancer. The drug is a souped-up version of thalidomide, a drug used to treat morning sickness that has caused thousands of birth defects, and has anti-cancer potential. Compared with thalidomide, it has fewer adverse reactions, and studies have shown that it does not cause birth defects in infants.

In September 2005, the FDA Oncologic Drugs Advisory Committee recommended that revlimid be used to treat infusion-dependent anemia. In October, the European Medicines Agency accepted revlimid's marketing application.

Celgene plans to submit a supplemental new drug application for this product for the treatment of relapsed refractory multiple myeloma to the US FDA and the European Medicines Agency in the first quarter of 2006.

Revlimid has effects on multiple biological pathways within cells. Celgene is still evaluating the product for the treatment of hematology and oncology, including multiple myeloma, myelodysplastic syndrome, chronic lymphocytic leukemia and solid tumors. Myelodysplastic syndrome is a malignant blood disease that affects approximately 300,000 people worldwide. Myelodysplastic syndrome occurs when the blood cells in the bone marrow remain immature and are unable to perform their necessary functions. The bone marrow becomes filled with these immature cells, which inhibit the development of normal cells. People with myelodysplastic syndrome must frequently rely on blood transfusions to combat symptoms such as anemia and fatigue, until they develop life-threatening iron overload or iron poisoning. The treatment of this disease urgently requires a fundamental approach rather than just symptom control. More than half of people diagnosed with myelodysplastic syndrome have chromosomal abnormalities in their cells, including partial or complete deletion of one or more chromosomes. The most common chromosomal abnormalities in myelodysplastic syndrome are deletions of chromosomes 5, 7, and 20. Another common mutation is an extra copy of chromosome 8. The proportion of chromosome 5q deletion in patients with myelodysplastic syndrome can reach 20% to 30%.